Positive data for Roche multiple sclerosis injection
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
KRKA holds 51% and Laurus Labs holds 49% shareholding
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
International Business is expected to register double-digit growth in constant currency terms
Subscribe To Our Newsletter & Stay Updated